Overview

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

Status:
Completed
Trial end date:
2012-10-22
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and when used in combination in subjects with COPD.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Albuterol
Ipratropium